These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
414 related articles for article (PubMed ID: 22804236)
1. Tumor-intrinsic and tumor-extrinsic factors impacting hsp90- targeted therapy. Alarcon SV; Mollapour M; Lee MJ; Tsutsumi S; Lee S; Kim YS; Prince T; Apolo AB; Giaccone G; Xu W; Neckers LM; Trepel JB Curr Mol Med; 2012 Nov; 12(9):1125-41. PubMed ID: 22804236 [TBL] [Abstract][Full Text] [Related]
2. The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models. Normant E; Paez G; West KA; Lim AR; Slocum KL; Tunkey C; McDougall J; Wylie AA; Robison K; Caliri K; Palombella VJ; Fritz CC Oncogene; 2011 Jun; 30(22):2581-6. PubMed ID: 21258415 [TBL] [Abstract][Full Text] [Related]
3. Hsp90 (heat shock protein 90) inhibitor occupancy is a direct determinant of client protein degradation and tumor growth arrest in vivo. Tillotson B; Slocum K; Coco J; Whitebread N; Thomas B; West KA; MacDougall J; Ge J; Ali JA; Palombella VJ; Normant E; Adams J; Fritz CC J Biol Chem; 2010 Dec; 285(51):39835-43. PubMed ID: 20940293 [TBL] [Abstract][Full Text] [Related]
4. Docosahexaenoic Acid-mediated Inhibition of Heat Shock Protein 90-p23 Chaperone Complex and Downstream Client Proteins in Lung and Breast Cancer. Mouradian M; Ma IV; Vicente ED; Kikawa KD; Pardini RS Nutr Cancer; 2017 Jan; 69(1):92-104. PubMed ID: 27880046 [TBL] [Abstract][Full Text] [Related]
5. Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Heuckmann JM; Balke-Want H; Malchers F; Peifer M; Sos ML; Koker M; Meder L; Lovly CM; Heukamp LC; Pao W; Küppers R; Thomas RK Clin Cancer Res; 2012 Sep; 18(17):4682-90. PubMed ID: 22912387 [TBL] [Abstract][Full Text] [Related]
6. Breast cancer and HSP90 inhibitors: is there a role beyond the HER2-positive subtype? De Mattos-Arruda L; Cortes J Breast; 2012 Aug; 21(4):604-7. PubMed ID: 22560618 [TBL] [Abstract][Full Text] [Related]
7. HSP90 inhibitors for cancer therapy and overcoming drug resistance. Jhaveri K; Modi S Adv Pharmacol; 2012; 65():471-517. PubMed ID: 22959035 [TBL] [Abstract][Full Text] [Related]
8. Hsp90: an emerging target for breast cancer therapy. Beliakoff J; Whitesell L Anticancer Drugs; 2004 Aug; 15(7):651-62. PubMed ID: 15269596 [TBL] [Abstract][Full Text] [Related]
9. Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development. Soga S; Akinaga S; Shiotsu Y Curr Pharm Des; 2013; 19(3):366-76. PubMed ID: 22920907 [TBL] [Abstract][Full Text] [Related]
11. Impact of Posttranslational Modifications on the Anticancer Activity of Hsp90 Inhibitors. Woodford MR; Dunn D; Miller JB; Jamal S; Neckers L; Mollapour M Adv Cancer Res; 2016; 129():31-50. PubMed ID: 26916000 [TBL] [Abstract][Full Text] [Related]
12. Development of a novel Hsp90 inhibitor NCT-50 as a potential anticancer agent for the treatment of non-small cell lung cancer. Hyun SY; Le HT; Nguyen CT; Yong YS; Boo HJ; Lee HJ; Lee JS; Min HY; Ann J; Chen J; Park HJ; Lee J; Lee HY Sci Rep; 2018 Sep; 8(1):13924. PubMed ID: 30224681 [TBL] [Abstract][Full Text] [Related]
13. Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth. Chandarlapaty S; Scaltriti M; Angelini P; Ye Q; Guzman M; Hudis CA; Norton L; Solit DB; Arribas J; Baselga J; Rosen N Oncogene; 2010 Jan; 29(3):325-34. PubMed ID: 19855434 [TBL] [Abstract][Full Text] [Related]
14. HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer. Schulz R; Streller F; Scheel AH; Rüschoff J; Reinert MC; Dobbelstein M; Marchenko ND; Moll UM Cell Death Dis; 2014 Jan; 5(1):e980. PubMed ID: 24384723 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Chen Z; Sasaki T; Tan X; Carretero J; Shimamura T; Li D; Xu C; Wang Y; Adelmant GO; Capelletti M; Lee HJ; Rodig SJ; Borgman C; Park SI; Kim HR; Padera R; Marto JA; Gray NS; Kung AL; Shapiro GI; Jänne PA; Wong KK Cancer Res; 2010 Dec; 70(23):9827-36. PubMed ID: 20952506 [TBL] [Abstract][Full Text] [Related]
16. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers. Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138 [TBL] [Abstract][Full Text] [Related]
17. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. Jensen MR; Schoepfer J; Radimerski T; Massey A; Guy CT; Brueggen J; Quadt C; Buckler A; Cozens R; Drysdale MJ; Garcia-Echeverria C; Chène P Breast Cancer Res; 2008; 10(2):R33. PubMed ID: 18430202 [TBL] [Abstract][Full Text] [Related]
18. Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis. Tsutsumi S; Neckers L Cancer Sci; 2007 Oct; 98(10):1536-9. PubMed ID: 17645779 [TBL] [Abstract][Full Text] [Related]
19. The achilles heel of ErbB-2/HER2: regulation by the Hsp90 chaperone machine and potential for pharmacological intervention. Citri A; Kochupurakkal BS; Yarden Y Cell Cycle; 2004 Jan; 3(1):51-60. PubMed ID: 14657666 [TBL] [Abstract][Full Text] [Related]
20. Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells. Tanimoto A; Yamada T; Nanjo S; Takeuchi S; Ebi H; Kita K; Matsumoto K; Yano S Oncotarget; 2014 Jul; 5(13):4920-8. PubMed ID: 24952482 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]